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2004;303:790–3.Transparent Interactive Decision Interrogator—Reply to Letter to the
Editor by Michael CooryTo the Editor—We thank Prof. Coory for his comments on our work
on the transparent interactive decision interrogator (TIDI). We
agree that TIDI cannot be applied to all scenarios in medical
decision making, certainly not in the form exactly presented in
our article in Value in Health [1]. This first version of TIDI was
developed as a proof-of-concept for an illustrative example in
antenatal care. Subsequently, a version of TIDI has been developed
for a real technology appraisal of biopharmaceuticals in the
treatment of psoriatic arthritis [2] to be test run within a real
reimbursement decision-making process by the National Institute
for Health and Clinical Excellence in the United Kingdom. In both
cases, the illustrative example and the real-life technology apprai-
sal, there was evidence available to populate the health-economic
model including the effectiveness data. TIDI was tailored to the
specific needs of these models. The software was, and still is,
however, at a proof-of-concept stage and it does not address all the
modeling issues. TIDI certainly does not have the ability to make
up for the lack of data; it can only facilitate the model interrogation
by using available evidence.
Despite its limitations, TIDI has a potential to be a useful tool
in exploring the boundaries of evidence. When long-term out-
comes, such as the 5-year survival rates in melanoma, are not
available, it is very difficult to make reimbursement decisions, we
agree. Systems such as TIDI, however, can enable decision
makers to carry out deterministic sensitivity analyses, for exam-
ple, of alternative extrapolation techniques to investigate the
effect of alternative assumptions on the estimates of cost-
effectiveness. Existing analogous evidence and/or background
knowledge can be built into TIDI to carry out analyses that would
help decision makers to make judgments about the relative
plausibility of different assumptions.
The version of TIDI presented in Value in Health, for the example
in antenatal care, focused mostly on the parameter uncertainty. It
can be tailored, however, to address other sources of uncertainty
such as structural uncertainty. The interrogator developed for the
psoriatic arthritis model allowed for sensitivity analyses of some
modeling assumptions, for example, alternative ways of modeling
utility and cost, alternative stopping rules for the Markov model, or
some subgroup analyses. TIDI can certainly be tailored to suit a
number of purposes and ways of dealing with uncertainty. For
example, methods of parameterizing structural uncertainty have
been developed that allow for a direct representation of the
uncertainty in the model, which can facilitate inferences about
the value of further research by estimating the expected value of
information [3]. TIDI can be adapted to facilitate this kind of
analysis. TIDI-like tools can also be designed to facilitate elicitation
of expert opinions, which can then be integrated in the model in
the form of prior distributions. Methods of elicitation of experts’
opinions have been already developed, for example, to parameter-
ize the structural uncertainty related to unknown long-termtreatment effects [4] and also to account and adjust for biases in
evidence synthesis [5]. Our future research will be focused on
designing TIDI methods for a range of commonly occurring
challenges in modeling in health technology assessment.
Prof. Coory is certainly making a valid point in saying that
discussions between experts of multidisciplinary teams are
required prior to obtaining the final model and ‘‘often several
iterations will be required to identify the critical inputs.’’ The
version of TIDI developed for the technology appraisal by the
National Institute for Health and Clinical Excellence was devel-
oped at the final stage of the modeling process when the
academic group commissioned to carry out the analysis achieved
consensus on the model structure following discussions between
clinical and statistical experts and health economists. It was
created with decision makers in mind to allow them to make
formal judgments about model assumptions, evidence, and
uncertainty. When analysts present the results to decision
makers, they are constrained to a limited number of scenarios
based on alternative modeling assumptions. TIDI facilitates the
construction of a potentially infinite number of scenarios, hence
avoiding limitations of the preprepared analysis. It can be
tailored to the needs of a specific decision problem regardless
of how small or big the problem is.
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in evidence synthesis. J R Stat Soc Ser A 2009;172:21–47.Rejoinder to Commentary: When Mapping Treatment Effects from
Disease-Specific to Generic Scales, Ordinary Least Squares Regression
Underestimates the Benefits of TreatmentTo the Editor—In our article, ‘‘Mapping from disease-specific to
generic health-related quality of life scales: a common factor
model’’ [1], we propose a method for mapping mean treatment
effects reported in trials on one scale into mean treatment effects
on another scale. Our approach is based on a structural equation
model that, in its simplest form, partitions the variances of
responses to all scales into two components. One component is
that part of the test that responds to treatment, and the other
component is the remaining variance. We show that the true
mapping coefficient is the signed square root of the ratio of the
variances of the first component. We also point out that the
ordinary least squares (OLS) regression coefficient will invariably
underestimate the true mapping, because of the measurement
error inherent in the test instruments.
One of the motivations of our approach, which is not men-
tioned by Palta, is that mappings between mean treatment effects
should be both invertible and transitive. In other words, suppose
we have estimated a mapping b^Y-Q from disease-specific instru-
ment Y to generic scale Q, then when we observe an estimated
treatment effect d^Y in a trial, we would predict an effect
d^Q¼ b^Y-Q d^Y on the generic scale Q. Note that d^Y is usually an
unbiased and consistent estimate for the true treatment
effect. On the other hand, by the same token, if we observe d^Q
(also unbiased and consistent) in a trial, we would predict
d^Y¼ d^Q=b^Y-Q on scale Y. In other words, b^Q-Y¼1=b^Y-Q . We show
that mappings defined our way have this property. They must
also be transitive, which means that a mapping from X to Z must
be the product of a mapping from X to Y and a mapping from
Y to Z.
In her commentary on our article, Palta [2] takes issue with our
approach on two grounds. First, she claims that the mean treat-
ment effect is still ‘‘prone to measurement error,’’ and therefore
that the ‘‘correct conversion is [still] the true mappingmultiplied by
the reliability of the DSM.’’ She goes on to assert that the correct
mapping coefficient to map from X to Y, for either an individual
score or an estimated mean score, is the OLS regression, which is
the ‘‘true’’ mapping that would be obtained if there were no
measurement error in X, multiplied by the reliability of X. In our
notation, her proposed mapping coefficient is
bOLSX-Y¼bX-YrX
It is easy to see that this will end in a contradiction.
The mean treatment effects on scales X and Y have variances
that depend on sample size, n in each arm, the variance of the
true scores s2X, and its reliability:
Varðd^XÞ¼
2t2X
n
¼ 2s
2
X
nrX
and Varðd^YÞ¼
2t2Y
n
¼ 2s
2
Y
nrY
Under Palta’s proposed mapping, d^Y¼bOLSX-Y d^X¼bX-YrXd^X, we
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This gives us that b2X-Y¼s2Y=s2Xr2XrY . But by parity of argument,
we can also obtain that b2Y-X¼
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which is true only when both reliabilities are 1 (clearly s2X,s
2
Y are
not equal to zero).
The same argument can be made in a less technical and
perhaps more intuitive way. Imagine a trial of infinite size in
which the treatment effect is examined on three test instruments
X, Y, and Z. The true mappings are—by definition—the ratios of the
treatment effects dX,dY ,dZ on each scale. These ratios obviously
do have, and must have, the properties of transitivity and
invertability. If we imagine, instead, a trial of finite size, the
ratios of the estimates must still represent estimates of the
mappings, which are still transitive and invertible.
But the OLS mappings proposed by Palta, even if they were all
estimated from a single (and infinite sized) cohort study, can never
have these properties and must always underestimate the correct
mappings. Indeed, with her method, if one mapped from X to Y,
then back to X, one would not end up where one started.
Similarly, one could map from X to Y, and then from Y to Z, but
this would end up with a different estimate than mapping from X
to Z, even if one had used data from a single cohort study with
observations on all three instruments.
The second criticism is that the assumptions made by the
common factor model may not necessarily be correct for every
test, and Palta gives an example where this appears to be the
case. We would accept entirely that the common factor
model—at least as we have presented it—may be inadequate
for some data sets. This is noted in Lu and Brazier [1] where
possible extensions are suggested. This, however, does not
change the fundamental point that when observations are made
under measurement error, mappings between mean treatment
effects based on OLS regression are incorrect and invariably
underestimate the correct mapping. As a result, estimates of
the quality of life gain due to treatment based on such methods
are invariably underestimates.G. Lu, MSc
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